NEW YORK (AP) — Boehringer Ingelheim Pharmaceuticals Inc. and Pfizer Inc. said Thursday the Food and Drug Administration approved Spiriva HandiHaler as a treatment for reducing symptoms and difficulty breathing because of chronic obstructive pulmonary disease. The inhalable drug is already approved as a once-daily maintenance treatment for breathing problems associated with the condition, also called COPD, which includes chronic bronchitis and emphysema. Symptoms associated with the condition include wheezing and difficulty breathing.
